Frequency analysis of HLA class I alleles in Iranian patients with progressive and non-progressive chronic lymphocytic leukemia

Hojjat‐Farsangi, Mohammad; Razavi, Seyed Mohsen; Sharifian, Ramazan Ali; Shokri, Fazel

doi:10.1016/j.humimm.2013.11.003

Cited by 5 publications

(6 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among other race/ethnic populations, increased CLL risk associations among Iranians have been reported for HLA‐A*11:01 (OR = 3.38, 95% CI = 1.16–10.55) and HLA‐B*35:01 (OR = 3.51, 95% CI = 1.48–8.6) and their combined haplotype ( P ‐value = 0.036), HLA‐DRB1*07 (OR = 2.19, 95% CI = 1.02–4.75), DQB1*06 (OR = 1.19, 95% CI = 1.13–3.2) and DRB1*13˜DQB1*03 haplotype (OR = 4.29, 95% CI = 1.29–15.75) . In the same population, decreased CLL risk was reported for HLA‐A*01:01 (OR = 0.34, 95% CI = 0.13–0.87), HLA‐A*26:01 (OR = 0.32, 95% CI = 0.10–0.92), HLA‐B*65:01 (OR = 0.17, 95% CI = 0.03–0.91), HLA‐B*53:01 (OR = 0.04, 95% CI = 0.01–0.32) and HLA‐DQB1*03 (OR = 0.58, 95% CI = 0.36–0.91).…”

Section: Chronic Lymphocytic Leukaemia/small Lymphocytic Lymphomamentioning

confidence: 99%

The role of HLA variation in lymphoma aetiology and survival

et al. 2019

View full text Add to dashboard Cite

Epidemiologic and laboratory evidence has consistently supported a strong inflammatory and immune component for lymphoma aetiology. These studies have consistently implicated variation in the immune gene, human leucocyte antigen (HLA), to be associated with lymphoma risk. In this review, we summarize the historical and recent evidence of HLA in both lymphoma aetiology and survival. The recent momentum in uncovering HLA associations has been propelled by the conduct of genome‐wide association studies (GWAS), which has permitted the evaluation of imputed HLA alleles in much larger sample sizes than historically feasible with allelotyping studies. Based on the culmination of smaller HLA typing studies and larger GWAS, we now recognize several HLA associations with Hodgkin (HL) and non‐Hodgkin lymphomas (NHLs) and their subtypes. Although other genetic variants have also been implicated with lymphoma risk, it is notable that HLA associations have been reported in every NHL and HL subtype evaluated to date. Both HLA class I and class II alleles have been linked with NHL and HL risk. It is notable that the associations identified are largely specific to each lymphoma subtype. However, pleiotropic HLA associations have also been observed. For example, rs10484561, which is in linkage disequilibrium with HLA‐DRB1*01:01˜DQA1*01:01˜DQB1*05:01, has been implicated in increased FL and DLBCL risk. Opposing HLA associations across subtypes have also been reported, such as for HLA‐A*01:01 which is associated with increased risk of EBV‐positive cHL but decreased risk of EBV‐negative cHL and chronic lymphocytic leukaemia/small cell lymphoma. Due to extensive linkage disequilibrium and allele/haplotypic variation across race/ethnicities, identification of causal alleles/haplotypes remains challenging. Follow‐up functional studies are needed to identify the specific immunological pathways responsible in the multifactorial aetiology of HL and NHL. Correlative studies linking HLA alleles with known molecular subtypes and HLA expression in the tumours are also needed. Finally, additional association studies investigating HLA diversity and lymphoma survival are also required to replicate initial associations reported to date.

show abstract

Section: Chronic Lymphocytic Leukaemia/small Lymphocytic Lymphomamentioning

confidence: 99%

The role of HLA variation in lymphoma aetiology and survival

et al. 2019

View full text Add to dashboard Cite

show abstract

“…There are several studies of the distributions of HLA alleles in diverse populations with CLL. For example, studies of Iranians with CLL reported increased frequencies of A*11:01, B*35:01, DRB1*07 and DRB1*06 are increased whereas A*01:01, A*26:01, B*65:01, B*53:01 and DRB1*03 are decreased [47,48]. Data from a large study of persons of predominately European descent with CLL reported a high degree of linkage disequilibrium between certain HLA alleles and HLA-haplotypes [49].…”

Section: Hla Associationsmentioning

confidence: 99%

The mystery of chronic lymphocytic leukemia (CLL): Why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology?

Yang

Gale

et al. 2015

Blood Reviews

View full text Add to dashboard Cite

“…Basaran et al [ 59 ] highlight the protective role of HLA-B35 against neoplastic transformation in patients with mycosis fungoides and Sézary syndrome. On the other hand, Hojjat-Farsangi et al [ 60 ] report a higher incidence of HLA-B*35:01 in patients with chronic lymphocytic leukemia. Also, Brazzelli et al [ 39 ] noticed an association between HLA-B*35 and mycosis fungoides.…”

Section: Discussionmentioning

confidence: 99%

Immunogenetic Background of Chronic Lymphoproliferative Disorders in Romanian Patients—Case Control Study

Tizu,

Calenic,

Maruntelu

et al. 2024

Medical Sciences

View full text Add to dashboard Cite

Background and Objectives: The implications of the genetic component in the initiation and development of chronic lymphoproliferative disorders have been the subject of intense research efforts. Some of the most important genes involved in the occurrence and evolution of these pathologies are the HLA genes. The aim of this study is to analyze, for the first time, possible associations between chronic lymphoproliferative diseases and certain HLA alleles in the Romanian population. Materials and Methods: This study included 38 patients with chronic lymphoproliferative disorders, diagnosed between 2021 and 2022 at Fundeni Clinical Institute, Bucharest, Romania, and 50 healthy controls. HLA class I and class II genes (HLA-A/B/C, HLA-DQB1/DPB1/DRB1) were investigated by doing high resolution genotyping using sequence specific primers (SSP). Results: Several HLA alleles were strongly associated with chronic lymphoproliferative disorders. The most important finding was that the HLA-C*02:02 (p = 0.002, OR = 1.101), and HLA-C*12:02 (p = 0.002, OR = 1.101) have a predisposing role in the development of chronic lymphoproliferative disorders. Moreover, we identified that HLA-A*11:01 (p = 0.01, OR = 0.16), HLA-B*35:02 (p = 0.037, OR = 0.94), HLA-B*81:01 (p = 0.037, OR = 0.94), HLA-C*07:02 (p = 0.036, OR = 0.34), HLA-DRB1*11:01 (p = 0.021, OR = 0.19), and HLA-DRB1*13:02 (p = 0.037, OR = 0.94), alleles have protective roles. Conclusions: Our study indicates that HLA-C*02:02 and HLA-C*12:02 are positively associated with chronic lymphoproliferative disorders for our Romanian patients while HLA-DRB1*11:01, HLA-DRB1*13:02, and HLA-B*35:02 alleles have a protective role against these diseases.

show abstract

Frequency analysis of HLA class I alleles in Iranian patients with progressive and non-progressive chronic lymphocytic leukemia

Cited by 5 publications

References 41 publications

The role of HLA variation in lymphoma aetiology and survival

The role of HLA variation in lymphoma aetiology and survival

The mystery of chronic lymphocytic leukemia (CLL): Why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology?

Immunogenetic Background of Chronic Lymphoproliferative Disorders in Romanian Patients—Case Control Study

Contact Info

Product

Resources

About